Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.

Slides:

Advertisements

Similar presentations

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Advertisements

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Axel Grothey Professor of Oncology Mayo Clinic Rochester

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Progesterone receptor nuclear morphology patterns in breast cancer.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Therapeutic validation in orthotopic lung PDX. (A).

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Detection rate for EGFR mutations in cfDNA.

Published online September 20, 2017 by JAMA Surgery

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Kaplan-Meier curves for overall survival (OS) probability.

Methods distribution among the three EQAs

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Clinical courses of patients.

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Health-related quality of life (HRQOL) results.

Proportion of continuous, intermittent, and limited (

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

(A) The stratified analysis for DFS because of the uncertain status of HER2, 132 patients could be calculated the recurrence risk score. (A) The stratified.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier plot of overall survival from the time of first dose of intrathecal interleukin-2 (IT IL-2) for all patients (A, n=43) and based on the extent.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Schema of the exploratory analyses (RAS wild-type population)

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking surgery or not, residual disease after.

Kaplan-Meier estimates for survival in metastatic disease for the whole patient cohort (A) and in patients with or without history of adjuvant trastuzumab.

Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors (in order, top to bottom): type of dose-dense.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS wild-type and (B) RAS wild-type/BRAF wild-type populations. Bev, bevacizumab; EGFRi, epidermal growth factor receptor inhibitor; P E A K , Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME, Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; Pmab, panitumumab; VEGFi, vascular endothelial growth factor inhibitor. Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS wild-type and (B) RAS wild-type/BRAF wild-type populations. Bev, bevacizumab; EGFRi, epidermal growth factor receptor inhibitor; P E A K , Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME, Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; Pmab, panitumumab; VEGFi, vascular endothelial growth factor inhibitor. Marc Peeters et al. ESMO Open 2018;3:e000297 Copyright © European Society for Medical Oncology. All rights reserved.